Kenta Biotech AG
  • Home
  • Shop
  • Events
  • Courses
  • Services
  • Pricing
  • Company
    • News
    • Success Stories
    • About Us
  • Appointment
  • Contact us
  • 0
  • +1 (718) 513-2983
  • Sign in
  • Contact Us
Kenta Biotech AG
  • 0
    • Home
    • Shop
    • Events
    • Courses
    • Services
    • Pricing
    • Company
      • News
      • Success Stories
      • About Us
    • Appointment
    • Contact us
  • +1 (718) 513-2983
  • Sign in
  • Contact Us
  1. Products
  2. Assay test kits
Public Pricelist
Public Pricelist
Sort By: Featured
Featured Newest Arrivals Name (A-Z) Price - Low to High Price - High to Low

Assay test kits

[0173-66005-5T-EU] BinaxNOW Malaria test Test 5 TESTS (EU)
BinaxNOW Malaria test Test 5 TESTS (EU)
128.00 € 128.0 EUR
[0173-660-000-25T-EU] BinaxNOW Malaria test Test 25 TESTS (EU)
BinaxNOW Malaria test Test 25 TESTS (EU)
304.00 € 304.0 EUR
[0173-430022] Binax Now RSV Tests 22/Test
Binax Now RSV Tests 22/Test
291.00 € 291.0 EUR
[0173-735025] Binax NOWTM STREP A (25 tests Test)
Binax NOWTM STREP A (25 tests Test)
180.50 € 180.5 EUR
[0441-B74-FRT] Bacterial Vaginosis RT-PCR Quant (CE) – 100 Tests
Bacterial Vaginosis RT-PCR Quant (CE) – 100 Tests
1,074.00 € 1074.0 EUR
[0900-TBS42034-100] Bacillus Species Detection Taqman qPCR - 100 Tests
Bacillus Species Detection Taqman qPCR - 100 Tests
557.00 € 557.0 EUR
[0996-G61RHA20-20T] BIOCREDIT COVID-19 Ag - 20 Tests
BIOCREDIT COVID-19 Ag - 20 Tests
110.00 € 110.0 EUR
[0173-735-025] BINAXNOW STREP A Test, 25 tests/Test
BINAXNOW STREP A Test, 25 tests/Test
141.00 € 141.0 EUR
[0881-5123221810-960] BACGene Salmonella spp. 10xHTP - 960 Tests
BACGene Salmonella spp. 10xHTP - 960 Tests
8,038.00 € 8038.0 EUR
[0881-5123221801-96] BACGene Salmonella spp. - 96 Tests
BACGene Salmonella spp. - 96 Tests
982.00 € 982.0 EUR
[0881-5123221811-10x96] BACGene Salmonella spp. - 10x96 Tests
BACGene Salmonella spp. - 10x96 Tests
8,164.00 € 8164.0 EUR
[0881-5123222110-960] BACGene Listeria spp. 10xHTP - 960 Tests
BACGene Listeria spp. 10xHTP - 960 Tests
8,038.00 € 8038.0 EUR
[0881-5123222111-960] BACGene Listeria spp. 10x96 - 960 Tests
BACGene Listeria spp. 10x96 - 960 Tests
8,164.00 € 8164.0 EUR
[0881-5123222101-96] BACGene Listeria spp. - 96 Tests
BACGene Listeria spp. - 96 Tests
982.00 € 982.0 EUR
[0881-5123222711-960] BACGene E.coli O157:H7 10x HTP - 960 Tests
BACGene E.coli O157:H7 10x HTP - 960 Tests
8,479.00 € 8479.0 EUR
[0881-5123222701-96] BACGene E.coli O157:H7 - 96 Tests
BACGene E.coli O157:H7 - 96 Tests
1,045.00 € 1045.0 EUR
[0597-PCR-V049-48R] Avian leukosis virus Rous sarcoma virus detection Tests -
Avian leukosis virus Rous sarcoma virus detection Tests -
1,127.50 € 1127.5 EUR
[0597-Oneq-V049-50R] Avian leukosis virus Rous sarcoma virus detection Tests
Avian leukosis virus Rous sarcoma virus detection Tests
1,492.00 € 1492.0 EUR
[0597-Oneq-V049-50R] Avian leukosis virus Rous sarcoma virus detection Tests
Avian leukosis virus Rous sarcoma virus detection Tests
1,492.00 € 1492.0 EUR
[0597-Oneq-V049-100R] Avian leukosis virus Rous sarcoma virus detection Tests
Avian leukosis virus Rous sarcoma virus detection Tests
1,942.00 € 1942.0 EUR
  • 3
  • 4
  • 5
  • 6
  • 7

Clear Filters



Respiratory syncytial virus (RSV) infections are the most common cause of hospitalization in early childhood, accounting for 57 000 to 120 000 hospitalizations each year in the United States. RSV is causing annual epidemics of bronchiolitis and pneumonia worldwide. In most cases the infection with RSV heals without sequelae, yet RSV infection can cause lung function deterioration and in some circumstances, years of recurrent wheezing or asthma may ensue. Overall RSV accounts for an estimated2% of the hospitalization rate among infants less than 1 year of age. This rate increases 4–5-fold among high-risk patients such as premature infants and those with chronic lung disease or complicated congenital heart disease.


Currently there is only one possibility to prevent infections of at-risk patients with RSV, namely immuno-prophylaxis with palivizumab/Synagis, marketed by MedImmune. However, the response to palivizumab is variable among individuals, and sometimes palivizumab fails to prevent RSV infections effectively.


Due to the lack of better antibodies, lack of effective anti-viral treatment and lack of an effective preventive vaccine for RSV, there is a substantial medical need for more efficacious prophylactic immunizations, e.g. by antibody.


Kenta Biotech had developed a fully human monoclonal antibody (KBRV201) derived from B-cells of a human donor. KBRV201 is of the human IgG1 isotype with specificity and very high affinity for the F-protein of human respiratory syncytial virus (hRSV). KBRV201 has been tested for recognition and neutralization of hRSV strains -A, -B and –Long, and KBRV201 could neutralize in vitro all strains tested with higher efficacy than other anti-F-protein mAb.




KBRV201 successfully recognizes 22 clinical isolates from children infected with RSV, including one isolate with a mutated F-protein. Overall KBRV201 has demonstrated superiority in every experiment performed, and KBRV201 is currently undergoing extensive testing in animal models.

14009 NW Harbor Ln, Portland, OR 97229, USA.


Follow us
Copyright © 2025 Kenta Biotech AG
English (UK) English (US)